|
[1] SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68 (1) :7-30.
|
|
[2] LOOS M, KLEEFF J, FRIESS H, et al. Surgical treatment of pancreatic cancer[J]. Ann N Y Acad Sci, 2008, 1138 (1) :169-180.
|
|
[3] OETTLE H, POST S, NEUHAUS P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer:A randomized controlled trial[J]. JAMA, 2007, 297 (3) :267-277.
|
|
[4] DU L, WANG-GILLAM A. Trends in neoadjuvant approaches in pancreatic cancer[J]. J Natl Compr Canc Netw, 2017, 15 (8) :1070-1077.
|
|
[5] KHORANA AA, MANGU PB, BERLIN J, et al. Potentially curable pancreatic cancer:American society of clinical oncology clinical practice guideline[J]. J Clin Oncol, 34 (21) :2541-2556.
|
|
[6] CLOYD JM, KATZ MH, PRAKASH L, et al. Preoperative therapy and pancreatoduodenectomy for pancreatic ductal adenocarcinoma:A 25-year single-institution experience[J]. J Gastrointest Surg, 2017, 21 (1) :164-174.
|
|
[7] MOKDAD AA, MINTER RM, ZHU H, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer:A propensity score matched analysis[J].J Clin Oncol, 2017, 35 (5) :515-522.
|
|
[8] VERSTEIJNE E, VOGEL JA, BESSELINK MG, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer[J]. Br J Surg, 2018, 105 (8) :946-958.
|
|
[9] HEINRICH S, PESTALOZZI BC, SCHFER M, et al. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head[J]. J Clin Oncol, 2008, 26 (15) :2526-2531.
|
|
[10] O'REILLY EM, PERELSHTEY NA, JARNAGIN WR, et al. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma[J]. Ann Surg, 2014, 260 (1) :142-148.
|
|
[11] MOTOI F, ISHIDA K, FUJISHIMA F, et al. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma:Results from a prospective multi-institutional phase 2 trial[J]. Ann Surg Oncol, 2013, 20 (12) :3794-3801.
|
|
[12] EVANS DB, VARADHACHARY GR, CRANE CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head[J]. J Clin Oncol, 2008, 26 (21) :3496-3502.
|
|
[13] VARADHACHARY GR, WOLFF RA, CRANE CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabinebased chemoradiation for resectable adenocarcinoma of the pancreatic head[J]. J Clin Oncol, 2008, 26 (21) :3487-3495.
|
|
[14] CASADEI R, di MARCO M, RICCI C, et al. Neoadjuvantchemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer:A single-center prospective, randomized, controlled trial which failed to achieve accrual targets[J]. J Gastrointest Surg, 2015, 19 (10) :1802-1812.
|
|
[15] CLOYD JM, CHEN HC, WANG X, et al. Chemotherapy versus chemoradiation as preoperative therapy for resectable pancreatic ductal adenocarcinoma:A propensity score adjusted analysis[J]. Pancreas, 2019, 48 (2) :216-222.
|
|
[16] van TIENHOVEN G, VERSTEIJNE E, SUKER M, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1) :A randomized, controlled, multicenter phase III trial[J]. J Clin Oncol, 2018, 36 (18_Suppl) :LBA4002-LBA4002.
|
|
[17] MOTOI F, KOSUGE T, UENO H, et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05) [J]. Jpn J Clin Oncol, 2019, 49 (2) :190-194.
|
|
[18] SOHAL D, McDONOUGH S, AHMAD SA, et al. SWOG S1505:Initial findings on eligibility and neoadjuvant chemotherapy experience with m FOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic adenocarcinoma[J]. J Clin Oncol, 2019, 39 (Suppl 4) :abstr414.
|
|
[19] de GEUS SW, ESKANDER MF, BLISS LA, et al. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma:A nationwide propensity score matched analysis[J]. Surgery, 2017, 161 (3) :592-601.
|
|
[20] DATTA SK, BELINI G, SINGH M, et al. Survival outcomes between surgery with adjuvant therapy compared to neoadjuvant therapy with surgery in stage I pancreatic adenocarcinoma:Results from a large national cancer database[R]. 2019 Gastrointestinal Cancers Symposium, 2019.
|
|
[21] LEE AJ, SIMONEAU E, CHIANG YJ, et al. Is early-stage pancreatic adenocarcinoma truly early:Stage migration on final pathology with surgery-first versus neoadjuvant therapy sequencing[J]. HPB (Oxford) , 2019.[Epub ahead of print]
|
|
[22] BAUGH KA, TRAN CAO HS, van BUREN G 2nd, et al. Understaging of clinical stage I pancreatic cancer and the impact of multimodality therapy[J]. Surgery, 2019, 165 (2) :307-314.
|
|
[23] NAGAKAWA Y, SAHARA Y, HOSOKAWA Y, et al. Clinical impact of neoadjuvant chemotherapy and chemoradiotherapy in borderline resectable pancreatic cancer:Analysis of 884 patients at facilities specializing in pancreatic surgery[J]. Ann Surg Oncol, 2019.[Epub ahead of print]
|
|
[24] MURPHY JE, WO JY, RYAN DP, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma:A phase 2 clinical trial[J]. JAMA Oncol, 2018, 4 (7) :963-969.
|
|
[25] KATZ MH, SHI Q, AHMAD SA, et al. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer:Alliance for clinical trials in oncology trial A021101[J]. JAMA Surg, 2016, 151 (8) :e161137.
|
|
[26] SUKER M, BEUMER BR, SADOT E, et al. FOLFIRINOX for locally advanced pancreatic cancer[J]. Lancet Oncol, 2016, 17 (6) :801-810.
|
|
[27] NITSCHE U, WENZEL P, SIVEKE JT, et al. Resectability after first-line FOLFIRINOX in initially unresectable locally advanced pancreatic cancer:A single-center experience[J].Ann Surg Oncol, 2015, 22 (Suppl 3) :s1212-s1220.
|
|
[28] POLISTINAF, COSTANTIN G, CASAMASSIMA F, et al. Unresectable locally advanced pancreatic cancer:A multimodal treatment using neoadjuvantchemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration[J]. Ann Surg Oncol, 2010, 17 (8) :2092-2101.
|
|
[29] LI X, GUO C, LI Q, et al. Association of modified-FOLFIRINOX-regimen-based neoadjuvant therapy with outcomes of locally advanced pancreatic cancer in Chinese population[J].Oncologist, 2019, 24 (3) :301-e93.
|
|
[30] BAI XL, SU RK, MA T, et al. Modified FOLFIRINOX for advanced pancreatic cancer:A tertiary center experience from China[J]. Chin J Surg, 2016, 54 (4) :270-275. (in Chinese) 白雪莉, 苏日嘎, 马涛, 等.改良FOLFIRINOX方案治疗进展期胰腺癌单中心经验[J].中华外科杂志, 2016, 54 (4) :270-275.
|
|
[31] LI X, MA T, ZHANG Q, et al. Modified-FOLFIRINOX in metastatic pancreatic cancer:A prospective study in Chinese population[J]. Cancer Lett, 2017, 406:22-26.
|
|
[32] von HOFF DD, ERVIN T, ARENA FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine[J]. N Engl J Med, 2013, 369 (18) :1691-1703.
|
|
[33] PETERSON SL, HUSNAIN M, POLLACK T, et al. Neoadjuvant nab-paclitaxel and gemcitabine in borderline resectable or locally advanced unresectable pancreatic adenocarcinoma in patients who are ineligible for FOLFIRINOX[J]. Anticancer Res, 2018, 38 (7) :4035-4039.
|
|
[34] MIYASAKA Y, OHTSUKA T, KIMURA R, et al. Neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel for borderline resectable pancreatic cancer potentially improves survival and facilitates surgery[J]. Ann Surg Oncol, 2019, 26 (5) :1528-1534.
|
|
[35] BLAIR AB, ROSATI LM, REZAEE N, et al. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer:The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy[J]. Surgery, 2018, 163 (5) :1090-1096.
|
|
[36] CHAPMAN BC, GLEISNER A, RIGG D, et al. Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensity-modulated radiation therapy (IMRT) in pancreatic adenocarcinoma[J]. J Surg Oncol, 2018, 117 (5) :1073-1083.
|
|
[37] KHAROFA J, MIERZWA M, OLOWOKURE O, et al. Pattern of marginal local failure in a phase ii trial of neoadjuvant chemotherapy and stereotactic body radiation therapy for resectable and borderline resectable pancreas cancer[J]. Am J Clin Oncol, 2019, 42 (3) :247-252.
|
|
[38] MICHELAKOS T, PERGOLINI I, CASTILLO CF, et al. Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX[J]. Ann Surg, 2019, 269 (4) :733-740.
|
|
[39] DHOLAKIA AS, HACKER-PRIETZ A, WILD AT, et al. Resection of borderline resectable pancreatic cancer after neoadjuvantchemoradiation does not depend on improved radiographic appearance of tumor-vessel relationships[J]. J Radiat Oncol, 2013, 2 (4) :413-425.
|
|
[40] WILLIAMS JL, KADERA BE, NGUYEN AH, et al. CA19-9normalization during pre-operative treatment predicts longer survival for patients with locally progressed pancreatic cancer[J]. J Gastrointest Surg, 2016, 20 (7) :1331-1342.
|
|
[41] TSAI S, GEORGE B, WITTMANN D, et al. Importance of normalization of CA19-9 levels following neoadjuvant therapy in patients with localized pancreatic cancer[J]. Ann Surg, 2018.[Epub ahead of print]
|
|
[42] MURAKAMI Y, UEMURA K, SUDO T, et al. Prognostic impact of normalization of serum tumor markers following neoadjuvant chemotherapy in patients with borderline resectable pancreatic carcinoma with arterial contact[J]. Cancer Chemother Pharmacol, 2017, 79 (4) :801-811.
|
|
[43] GALL TMH, BELETE S, KHANDERIA E, et al. Circulating tumor cells and cell-free DNA in pancreatic ductal adenocarcinoma[J]. Am J Pathol, 2019, 189 (1) :71-81.
|
|
[44] WEI T, ZHANG Q, LI X, et al. Monitoring tumor burden in response to FOLFIRINOX chemotherapy via profiling circulating cell-free DNA in pancreatic cancer[J]. Mol Cancer Ther, 2019, 18 (1) :196-203.
|
|
[45] SANDINI M, PATINO M, FERRONE CR, et al. Association between changes in body composition and neoadjuvant treatment for pancreatic cancer[J]. JAMA Surg, 2018, 153 (9) :809-815.
|
|
[46] BARNES CA, KREPLINE AN, ALDAKKAK M, et al. Is adjuvant therapy necessary for all patients with localized pancreatic cancer who have received neoadjuvant therapy?[J]. J Gastrointest Surg, 2017, 21 (11) :1793-1803.
|
DownLoad: